The small G proteins of the RAS superfamily act as molecular switches in the transduction of cellular signals critical for a wide range of normal developmental events as well as pathological processes. However, the functions of Ras genes in ovarian cells have only started to be unveiled. RAS, most likely KRAS that is highly expressed in granulosa cells of growing follicles, appears crucial for mediating the gonadotropin-induced events associated with the unique physiological process of ovulation. R AS (rat sarcoma viral oncogene) proteins function as molecular switches regulated at the level of GDP/GTP binding and play critical roles in controlling normal cellular proliferation as well as in the development of neoplasia. Activating mutations in the Ras gene family members are found in 30% of all human tumors (1). In mammals, there are three functional Ras genes, H(Harvey)ras, N(neuroblastoma)ras, and K(Kirsten)ras, located on different chromosomes that appear to be expressed ubiquitously (2). In addition, genes encoding three other small G proteins, R(related)ras, Rras2 (TC21), and M(muscle)ras are structurally and functionally related members of this family (3) and can impact cell motility, cell adhesion, and transformation (4 -6). The first 86 amino acids of the mammalian HRAS, NRAS, and KRAS proteins, which harbor the putative effector domain, are 100% identical.
R
AS (rat sarcoma viral oncogene) proteins function as molecular switches regulated at the level of GDP/GTP binding and play critical roles in controlling normal cellular proliferation as well as in the development of neoplasia. Activating mutations in the Ras gene family members are found in 30% of all human tumors (1) . In mammals, there are three functional Ras genes, H(Harvey)ras, N(neuroblastoma)ras, and K(Kirsten)ras, located on different chromosomes that appear to be expressed ubiquitously (2) . In addition, genes encoding three other small G proteins, R(related)ras, Rras2 (TC21), and M(muscle)ras are structurally and functionally related members of this family (3) and can impact cell motility, cell adhesion, and transformation (4 -6) . The first 86 amino acids of the mammalian HRAS, NRAS, and KRAS proteins, which harbor the putative effector domain, are 100% identical.
Despite the diverse functions of these RAS proteins in various signal transduction events, Nras and Hras are nonessential for mouse development. Mice that are homozygous null for either Nras (7) or Hras (8) are viable and exhibit no overt developmental or postnatal abnormalities. However, embryos homozygous null for Kras die between 12 and 14 d of gestation, with liver defects and evidence of anemia, suggesting that Kras is the only Ras family member that is crucial for embryonic development and cannot be compensated for by other Ras genes, assuming that they are expressed at these early embryonic stages (9) . RAS proteins transduce signals through different effectors [e.g. Ras-activated factor (serine/threonine kinase), phosphatidylinositol 3-kinase (PI3K), RAL-guanine nucleotide dissociation stimulator (GDS), and RAS-guanine nucleotide release protein (GAP)], which regulate diverse cell functions. They become oncogenic by single point muta-tions, mainly at either codon 12 or 13, which lead to constitutive signaling and cell transformation associated with changes in cell morphology, increased proliferation, and/or inhibition of apoptosis (10 -12) . RAS proteins can also induce cell senescence, most frequently associated with epithelial cells and fibroblasts (13) (14) (15) .
Despite the extensive involvement of RAS factors in activating normal signal transduction and aberrant tumorigenesis of eukaryotic cells, the potential roles of RAS in mediating the effects of hormones and growth factors in ovarian granulosa cells (16, 17) and the physiological functions of Ras in the ovary have only started to be unraveled (18) . The embryonic lethality of Kras knockout mice and the inconvenience of primary ovarian cells as tools for biochemical studies have prevented the study of Ras with respect to mammalian reproductive biology in vivo. However, the recent development of mouse strains carrying Ras conditional mutant alleles and tissue-specific expressed Cre recombinase have permitted us to investigate the roles of KRAS in specific ovarian cell types (18, 19) . In this minireview, we summarize recent studies of the physiological and pathological functions of RAS in the rodent ovary and discuss how the Ras mutant mouse models may provide models to help understand human diseases such as premature ovarian failure (POF) and ovarian cancers.
Physiological Functions of RAS in the Rodent Ovary
The mammalian ovary controls female fertility by regulating the continuous growth and timely maturation of follicles destined to ovulate and release a fertilizable oocyte (egg). Formation of the progesterone-producing corpus luteum after ovulation is requisite for successful initiation of pregnancy. Moreover, within growing follicles, it is now clear that the oocyte and its surrounding somatic cells, the cumulus cells, comprise a unique microenvironment. Before ovulation, the cumulus cell-oocyte complex undergoes dramatic changes that are required for successful ovulation and oocyte maturation. Collectively, these ovarian events are regulated by the coordinate production and action of local ovarian regulatory factors (steroids and proteins) and the pituitary gonadotropins, FSH and LH (20 -22) . FSH and LH bind their cognate seven-transmembrane, Gs protein-coupled receptors (GPCRs), FSH receptor, and LH chorionic gonadotropin receptor, respectively, and thereby increase intracellular cAMP and activate protein kinase A (PKA) (23) . Although the canonical cAMP and PKA pathway is critical for many ovarian cell functions, recent studies indicate that the signaling events controlled by FSH and LH via their receptors in ovarian granulosa cells are more complex. Some molecular events, such as the phosphorylation of protein kinase B (PKB/AKT) and MAPKs (also known as ERKs), can occur independently of PKA activation (16, 23, 24) . The FSH and LH receptors, like other GPCRs, can activate RAS and specific tyrosine kinase cascades, a pattern that has been established for GPCRs in other cells (25) (26) (27) . The facts that LH via its receptor can activate RAS in an MA10 mouse Leydig cell line and that activation of RAS induces phosphorylation of ERK1/2 via a receptor tyrosine kinase-dependent mechanism (28) provide support for the notion that gonadotropin receptors are also linked functionally to RAS and tyrosine kinase activities.
Although LH directly stimulates functional changes in theca cells and granulosa cells of preovulatory follicles, its effects on cumulus cells and oocytes are probably indirect. In mice, these cells, in contrast to granulosa cells, express few or no LH receptors (LH chorionic gonadotropin receptors) and fail to respond when directly stimulated by LH in culture (29) . In recent years, members of the epidermal growth factor (EGF)-like growth factor family have emerged as likely mediators of LH action in the preovulatory follicle. Specifically, the pioneering studies of Espey, Conti, and others (29 -33) have shown that amphiregulin (AREG), epiregulin (EREG), and betacellulin (BTC) are induced rapidly by LH or its analog human chorionic gonadotropin (hCG) in granulosa cells and cumulus cells. These factors are thought to function by both autocrine and paracrine mechanisms to propagate LH signals throughout the preovulatory follicle to induce ovulation, cumulus cell-oocyte complex (COC) expansion, oocyte maturation, and luteinization (29, 31, 32) . The growth factor effects require the EGF receptor (EGFR, also called ERBB1), because EGFR tyrosine kinase inhibitors and disruption of the EGF signaling network in vivo block COC expansion and ovulation (31, 32) .
Recently and of physiological relevance, activation of RAS in granulosa cells by the gonadotropins has also been documented in vivo. In the mouse ovary, KRAS is highly expressed in granulosa cells of small and large growing follicles and at lower levels in luteal cells (18) (Fig. 1A) . During hormone-induced ovulation, the levels of total RAS do not change. However, the levels of active, GTPbound RAS that are undetectable in ovaries of immature mice, increased slightly in response to the FSH-like gonadotropin equine chorionic gonadotropin (eCG) that stimulates preovulatory follicle development. Activated RAS was increased markedly (but transiently) at 2 h after hCG treatment that stimulates ovulation. Notably, hCG also induces significant phosphorylation of the EGFR, MAPK kinase (MEK)-1/2, and ERK1/2, all maximal at ;Amhr2-Cre mutant mice (3 months of age). KRAS is also present in corpora lutea (CL) of WT mice (3 months of age) and in hormonally primed immature mice 48 h after hCG. KRAS is also present in oocytes. B, Ovarian histology and functional outcomes of RAS activation during physiological and pathological conditions. In the normal ovary, LH induction of ovulation and luteinization is dependent on the activation of RAS and the downstream kinases ERK1/2. Premature exposure of granulosa cells to constitutively active KRAS G12D leads to the formation of abnormal follicles in which the granulosa cells cease to divide, are nonapoptotic, and fail to express markers of granulosa cell differentiation. Of note, the Kras gene is silenced in the cells within the abnormal follicles (A), but they express high levels of PTEN and Zbtb16 (Pzlf) (19 More recently, ERK1/2, the downstream target kinases of the EGFR/RAS pathway have been disrupted in granulosa cells, and these mutations cause dramatic changes in granulosa cell fate. Although follicular development is normal in the Erk1/2 mutant mice, they are completely infertile because ovulation, COC expansion, and oocyte maturation as well as luteinization are all blocked (34) . The global effects of disrupting Erk1/2 in granulosa cells demonstrate the critical importance of ERK1/2 activation in mediating LH action at the ovulatory stage of follicular development in vivo (32, 34, 35) . Additionally, the transcription factor CAAT/enhancer binding protein-␤ (C/ EBP␤) is a target of ERK1/2 and appears to control some of the cell fate decisions in granulosa cells of ovulatory follicles (34, 36) . This is most likely associated with cell cycle arrest based on the impact of C/EBP␤ in other endocrine tissues such as uterine stromal cells (37) and adipocytes (38) as well as its connections with senescence in fibroblasts (39, 40) . Interestingly, cell cycle arrest in each of these cell types appears to involve the production of potent cytokines such as IL-6 (37, 38, 40, 41) . LRH1 (nuclear receptor liver receptor homolog 1 also known as NR5A2) is a transcription factor highly similar in structure to steroidogenic factor 1 (SF1; NR5A1). Although both are expressed in granulosa cells of growing follicles, recent studies indicate that LRH1, rather that SF1, is a potential RAS-ERK1/2 target in granulosa cells of preovulatory follicles. Specifically, mice in which the Lrh1 gene is conditionally disrupted in granulosa cells show ovulation and luteinization defects (42), whereas conditional disruption of Nr5a1 in granulosa cells selectively impairs early stages of follicle growth (43) . In addition, LRH1 is known to be phosphorylated and functionally activated by ERK1/2 (44) .
Therefore, RAS, most likely KRAS, is an important physiological mediator of gonadotropin signaling in ovarian follicles, especially at the time of ovulation when activation of ERK1/2 is essential not only for follicle rupture but also for oocyte meiotic maturation, COC expansion, and luteinization (34, 45) . Thus, at the preovulatory stage of follicular growth, RAS and ERK1/2 activation are obligatory to direct the terminal differentiation of granulosa cells to nondividing luteal cells (34) (Fig. 1, A and B). Because follicular growth was normal in mice in which ERK1/2 were depleted in granulosa cells and because the activation of RAS in granulosa cells was lower in response to FSH/eCG in vivo, one might predict that activated RAS and ERK1/2 are not essential and might even exert pathological effects at earlier stages of follicle growth.
Granulosa Cell-Specific Kras

G12D Mutation Causes Stage-Dependent Ovarian Defects
The effects of Ras gene mutations have been studied in primary and transformed cell lines as well as in transgenic mice (11, 46) . However, traditional mutation strategies direct expression of the oncogenes to specific cells of the target tissue based on promoter activity and may lead to supraphysiological levels of expression. In an effort to overcome these limitations, Tyler Jacks and colleagues (47, 48) have created new mouse strains harboring latent, oncogenic alleles of Kras and Nras capable of tissue-and cell type-specific activation in vivo, triggered by CRE recombinase-mediated DNA recombination. Mice expressing a germline Kras G12D mutation exhibit early embryonic lethality due to a placental trophoblast defect (49) . Mutant embryos demonstrate cardiovascular and hematopoietic defects as well as a profound defect in lung branching morphogenesis associated with up-regulation of the MAPK antagonist Sprouty-2 and abnormal activation of MAPK within the lung epithelium (50) .
To analyze the functions of RAS protein in ovarian cells in vivo, several mouse models have been generated (Table 1) (19, 56, 57) . By contrast, Cyp19-Cre is highest in granulosa cells of antral and preovulatory follicles but is absent from OSE cells (18, 58) . Although Cyp19-Cre is expressed in a subset of granulosa cells in preantral and early antral follicles, the Cre transgene is highly expressed in all the granulosa cells of preovulatory follicles and induces 90 -100% DNA excision of target genes (18, 58) . Because the progesterone receptor (Pgr) is expressed only in granulosa cells of preovulatory follicles exposed to the LH surge, Cre recombinase is active only in luteinizing granulosa cells after the LH surge in the Pgr-Cre mice (59). The Kras G12D ;Amhr2-Cre and Kras G12D ;Cyp19-Cre conditional mutant mice were subfertile in the first 3 months of age and became completely infertile thereafter (18) . Further studies demonstrated that the adult Kras G12D mutant mice have few healthy growing follicles in their ovaries and very low levels of estrogen but high levels of serum gonadotropins. Thus, the mice exhibit the symptoms similar to POF in human patients. More surprisingly, the ovaries of these Kras G12D ;Amhr2-Cre and Kras G12D ;Cyp19-Cre mice contain many small abnormal follicle-like structures in which the granulosa cells are nonmitotic and nonapoptotic and fail to express known markers of granulosa cell differentiation, including FSH and LH receptors (18) (Fig.  1, A and B) . As a consequence of KRAS G12D expression, their development is arrested at a very early stage of follicle growth, and they fail to either differentiate or die. Importantly, expression of KRAS G12D in granulosa cells silenced the endogenous Kras gene such that neither Kras mRNA nor protein could be detected in the abnormal cells. As a consequence, expression of KRAS G12D in granulosa cells did not stimulate granulosa cell proliferation (Fig. 1A) .
In mice that carry the granulosa cell-specific Kras G12D mutations (induced by Amhr2-Cre or Cyp19-Cre), the few follicles that are not arrested at an early stage of development proceed to the antral stage. However, these Kras G12D antral follicles fail to ovulate and express reduced levels of ovulation-related genes, such as Areg, Ptgs2, Has2, and Tnfaip6 (18) . Consequently, two prerequisites of successful ovulation, meiotic resumption in oocytes and expansion of COCs, are compromised in the ovaries of the Kras mutant mice. Not surprisingly, the number of oocytes being ovulated was reduced markedly in these animals. However, the granulosa cells luteinize and form corpora lutea although with abnormal looking histology and entrapped oocytes. Interestingly, oocytes retrieved from the few preovulatory follicles that develop in the eCG-primed Kras mutant mice are able to undergo spontaneous meiotic maturation in a manner similar to those isolated from wild-type mice. The mature eggs occasionally being ovulated by Kras mutant mice can be fertilized and undergo normal embryonic development (Fan, H.-Y., and J. S. Richards, unpublished observations). In addition to these defects observed in vivo, when Kras G12D was expressed in cultured cells using adenoviral Cre approaches, the expression of FSH and LH receptors (Fshr and Lhcgr) was decreased, and the response of the cells to ovulatory signals was blocked (18) . Collectively, these observations indicate that the observed effects of Kras G12D on ovarian follicles are context and granulosa cell specific. That is, expression of KRAS G12D in small follicles causes growth arrest, whereas expression at later stages of follicle development impairs ovulation but not oocyte functions (19) . If expressed after the LH surge as in the Pgr-Cre mice, KRAS G12D appears to exert no overt effects (19) .
The eCG-and hCG-stimulated phosphorylation of ERK1/2 observed in granulosa cells of ovulatory follicles of wild-type mice was reduced markedly in Kras G12D mutant granulosa cells (18) . Reduced ERK1/2 phosphorylation was due, in part, to increased expression of MAPK phosphatase MKP3 [also known as duel-specific phosphatase 6 (DUSP6)], an ERK1/2-specific phosphatase. Kras G12D expression in granulosa cells leads to the upregulation of Mkp3/Dusp6 levels both in vivo and in vitro. Interestingly, in our previous studies, Dusp6 was also identified as a gene being induced dramatically in mouse granulosa/cumulus cells by LH surge (30) . In the eCG/hCG-induced ovulation model, the maximal expression of Dusp6 was observed at 4 h after hCG treatment, when the transient preovulatory phosphorylation of ERK1/2 is terminated. Depletion of Dusp6 in granulosa cells by RNA interference prolonged the AREG-induced ERK1/2 phosphorylation in culture. In addition, ERK1/2 apparently induces the expression of Dusp6, because the MEK1/2 inhibitor U0126 blocks AREG-induced Dusp6 expression in cultured granulosa cells, and hCG treatment fails to induce Dusp6 expression in ovaries from mice carrying granulosa cell-specific mutations of ERK1/2 (18, 34) . Expression levels of Sprouty-2 (as well as two other mammalian Sprouty family members, Spry 1 and 4), a MAPK antagonist that is selectively up-regulated by KRAS G12D in mouse lung epithelium (50), do not change in Kras mutant granulosa cells (Fan, H.-Y., and J. S. Richards, unpublished observations). These results suggest that although KRAS G12D attenuates the activity of MAPK cascade in both developing lung branches and ovarian follicles, it achieves these effects by inducing different antagonists of this pathway. Collectively, these data indicate that Dusp6 is one negative feedback regulator of ERK1/2 activity, being induced in both physiological conditions and Kras mutant conditions.
Kras Mutation and Cell Cycle Arrest in Granulosa Cells
As mentioned above, Kras G12D expression in granulosa cells at early (secondary/preantral) stages of follicle growth induces the formation of many abnormal follicle-like structures in which the granulosa cells are nonmitotic, nonapoptotic, and poorly differentiated (18) (Fig. 1, A and B) . That the formation of these abnormal follicle-like structures is dependent on the stage of granulosa cell differentiation and follicle development (18, 19) was demonstrated by their presence in the ovaries of Kras G12D ;Amhr2-Cre and Kras G12D ;Cyp19-Cre mice where recombinase is expressed in granulosa cells of small growing follicles. By contrast, the abnormal follicles were not observed in the Kras G12D ;Pgr-Cre mutant mice where recombination occurs only after the LH surge (19) . Moreover, the absence of any ovarian defects in the Kras G12D ;Pgr-Cre mutant mice indicates that constitutively active KRAS does not impact the fate of granulosa cells that have already been exposed to RAS activation initiated by the LH surge.
Overexpression of oncogenic Kras mutants not only renders cells susceptible to tumorigenesis but can also induce premature senescence in some primary cell cultures as well as in some cells, most notably epithelial cells and fibroblasts, in vivo (13, 46) . In these cell types, the senescent response is associated with, and regulated by, increased levels of cell cycle inhibitors such as p15 INK4B , p16
INK4A
, and the tumor repressor p53 (13, 46, 60) . Senescence in some cell types appears to be dependent on ERK1/2 and ribosomal S6 kinase activation of C/EBP␤ (61) . It is also associated with a highly predictable and elevated pattern of secreted cytokines, such as IL-6 (40, 62 , and p53 and induce cell cycle arrest in cultured granulosa cells (19) . These results suggest that endogenous levels of oncogenic Kras likely induce cell cycle arrest of granulosa cell by a mechanism that is distinct and apparently independent of the known p15 INK4B /p16 INK4A /p53 pathway. However, the canonical cell senescence pathway induced by high levels of oncogenic Ras mutations is conserved in granulosa cells.
Although the detailed mechanisms by which endogenous levels of Kras G12D lead to cell cycle arrest of granulosa cells remain unknown, recent results indicate that it involves the rapid silencing of Kras gene itself (mediated by activated ERK1/2 and/or C/EBP␤?) and the up-regulation of tumor repressor Pten. Loss of KRAS and increased phosphatase with tensin homolog (PTEN) lead secondarily to the absence of both phospho-ERK1/2 and phospho-AKT in the mutant cells (19) (Fig. 1B) . In addition, the Kras
G12D
-expressing granulosa cells exhibit markedly reduced levels of the cell cycle activators cyclin A, cyclin D2, and E2F1 and increased levels of Zbtb16 (Plzf), a regulator of cell cycle arrest. Because activation of endogenous Kras G12D mutant gene in cultured granulosa cells by Cremediated DNA recombination did not induce cell cycle arrest, the stage of follicular development and granulosa cells differentiation dictated by the follicular microenvironment appear to be crucial for the Kras-induced inhibitory effects on granulosa cell proliferation (19) .
Pathological Effects of Ras Mutations and Ovarian Cancer
As indicated above, about 30% of human tumors carry Ras gene mutations (1) . Of the oncogenic genes in this family, Kras is the most frequently mutated member in human tumors, including adenocarcinomas of the pancreas (ϳ70 -90% incidence) (10), colon (ϳ50%) (48) , and lung (ϳ25-50%) (47) . The Kras G12D conditional knock-in mouse model has been extensively employed to study the mechanisms of Ras-induced tumor develop-ment (47, 50, 53) . The conditional expression of Kras G12D in mice, when combined with other mutations, leads to malignant tumorigenesis in various tissues, including lung, mammary gland, OSE, and uterus (46, 50, 53) (Wang, J., and F. J. DeMayo, personal communications). The responses of cells to RAS activation appear to be context, developmental, and strength specific such that cells may either undergo oncogenic transformation or become senescent (46) . In the ovary, it is now clear that granulosa cells respond to Kras G12D mutant protein and undergo cell cycle arrest, whereas the surface epithelial cells respond to the same mutation and become hyperproliferative.
OSE cancers make up nearly 90% of all ovarian cancers. In contrast, only 5% of human ovarian cancers are derived from granulosa cells (63, 64) . This seems unexpected because granulosa cells are the most abundant proliferative cell type in growing follicles. The low incidence of granulosa cell tumors (GCTs) is likely due to the strong resistance of granulosa cells to specific oncogenic stimuli. In addition, granulosa cells are removed routinely and systematically from the growing pool by apoptosis or by terminal differentiation to nondividing luteal cells (luteinization). Thus, unlike many other cell types, granulosa cells may escape most of the rare occurrences of oncogenic mutations. One recent exception appears to be the mutation of Foxl2, a transcription factor important for early follicle development and granulosa cell proliferation, that has been associated with human adult GCTs (65) . Known mutant mouse models exhibiting high frequencies of granulosa tumor development include inhibin-␣-null mice (66, 67) , granulosa cell-specific Smad1/ 5/8 knockout mice (68) , and granulosa cell-specific ␤-catenin mutant mice (69, 70) . None of these models appears to involve RAS-regulated signaling events. Because most cancer cells express more than one mutant gene, numerous studies, including those in ovarian cells, have been done to determine the effects of different combinations of oncogenic factors, caused by both activating as well as inactivating mutations (64) .
The tumor suppressor PTEN is often disrupted in many tumor cells (71, 72) . As a potent inhibitor of the PI3K pathway, PTEN impacts the phosphorylation and functional status of several factors, including, AKT and Forkhead box O (FOXO) factors. Because FOXO1 is elevated in granulosa cells of growing follicles (73, 74) , we generated conditional disruption of the Pten gene in granulosa cells using the Amhr2-Cre and Cyp19-Cre mouse strains. Mice in which Pten alone was disrupted in granulosa cells develop GCTs but with a very low frequency (75 ;Amhr2-Cre mice exhibit enhanced ovulation, reduced apoptosis (associated with reduced levels of FOXO1), and contain corpora lutea with an extended life span (58) . By contrast, when Pten is disrupted in the Kras mutant strain of mice, the Pten fl/fl ;Kras G12D ;Amhr2-Cre but not the Pten fl/fl ; Kras G12D ;Cyp19-Cre double-mutant mice develop OSE tumors. The specificity of OSE tumor formation is due to the expression of the Amhr2 but not Cyp19 in OSE cells (19) . The epithelial cells of these tumors express cytokeratin 8, WT1, and MUC16, suggesting that they are serous adenocarcinomas (76) . As might be expected, the mutant cells exhibit elevated activities of the ERK1/2 pathway and PI3K/AKT pathways. Strikingly, the Pten fl/fl ;Kras G12D double-mutant mice do not develop GCTs. Rather, the abnormal follicle-like structures containing granulosa cells in cell cycle arrest form as in the Kras single-mutant mice and are not rendered tumorigenic by disruption of the Pten gene (19) . That the Kras G12D /Pten mutant granulosa cells do not undergo tumorigenic transformation is quite unique and indicates that these cells are extremely resistant to this specific combination of oncogenic insults. These cells appear to have robust self-protecting mechanisms against these specific mutations to limit cell cycle progression but at the expense of normal reproductive functions. Thus, within the ovaries of the same Kras G12D /Pten mutant mouse, granulosa cells exit the cell cycle, whereas the OSE becomes hyperplastic. Therefore, the Kras G12D /Pten double-mutant mice afford a unique model in which to track two opposing cell cycle forces, cell cycle arrest vs. proliferation, and to determine why early granulosa cells and OSE cells are susceptible to their dramatically altered fates and what cell signaling cascades, genes, and/or epigenetic factors downstream of KRAS dictate these effects.
Contrary to the lack of granulosa cell tumors (GCTs) in Pten fl/fl ;Amhr2-Cre or Kras G12D ;Amhr2-Cre mutant mice, mice in which Smad1/5/8 (68) or Inha (encoding inhibin 2) (66) are disrupted develop GCTs with 100% penetrance. In addition, mice that express dominant active ␤-catenin alone in granulosa cells develop GCTs. The recombined Ctnnb1 flox(ex3) allele encodes a ␤-catenin protein that, although still functional, lacks a series of phosphorylation sites that are required for its degradation, resulting in its inappropriate accumulation and translocation to the nucleus. Interestingly, Ctnnb1 flox(ex3)/ϩ ;Amhr2-Cre mice developed pretumor follicle lesions, which consist of follicle-like nests of disorganized, pleiomorphic granulosa cells. These pretumor lesions grow no larger than the size of antral follicles but often evolved into GCT in older mice. These data showed a causal link between misregulated Wnt/␤-catenin signaling and GCT development (69, 70 
Clinical Implications
Based on the foregoing review, it is clear that the role of RAS, most likely KRAS, in the ovary is cell context specific. Moreover, RAS activation is tightly regulated in granulosa cells and OSE cells. Whereas the activation of RAS is critical for initiating LH-mediated events, such as ERK1/2 phosphorylation, that are essential for ovulation and luteinization, inappropriate expression of a mutant constitutively active form of KRAS (KRAS G12D ) leads to granulosa cell cycle arrest and impaired follicle growth. By contrast, expression of KRAS G12D in Pten-deficient OSE cells leads to serous epithelial adenocarcinomas. Thus, mutations in RAS could be associated with some unknown causes of POF as well as ovarian cancer. In addition, because POF is often associated with elevated levels of FSH and because FSH can activate RAS in granulosa cells in culture and in vivo (albeit to a lesser extent than LH), it is possible that prolonged stimulation of granulosa cells by FSH could also inappropriately activates RAS, thereby impairing their functions and causing cell cycle arrest. Importantly, prolonged exposure of mouse ovaries to FSH does not lead to ovarian cancer (77) . RAS may be involved in polycystic ovarian syndrome where levels of LH but not FSH are elevated. In this scenario, RAS may be activated inappropriately in theca cells. Chronic levels of LH have also been shown to cause benign ovarian luteomas in mice (78) ; hence, similar effects may impact ovarian cells in postmenopausal women. Curiously, the RAS mutations that impact granulosa cells and OSE cells do not cause testicular tumors, but other aspects of male fertility have not been examined in detail. Thus, the most important physiological function of RAS in the gonads is its activation at the time of ovulation. In this regard, it is important to note that induction of the LH surge is an ERK1/2-dependent event that, although not yet known, is likely a RAS-dependent event as well (79) . ERK1/2 is not critical for basal LH secretion in male mice. The most important pathological effects of RAS activation in the ovary appears to be the potent effect of mutant RAS to cause cell cycle arrest in granulosa cells and facilitate OSE cancer.
Future Directions
Although many factors that control cell cycle progression and transformation have been identified and their functions characterized, less is known about what causes cells to exit the cell cycle and become quiescent, senescent, or terminally differentiated. If the factors that force cells to exit the cell cycle irreversibly were known and their functions understood, these factors might be harnessed to provide new avenues, reagents, and approaches to block cancer cell proliferation. We hypothesize that specific regulatory molecules, in response to the activation of the endogenous RAS (KRAS) in granulosa cells of preovulatory follicles, cause the transformation of these proliferating granulosa cells to nondividing terminally differentiated luteal cells. Premature expression of the oncogenic Kras G12D mutant in granulosa cells of small follicles dictates their premature exit from the cell cycle and renders them uniquely impervious to insults by specific oncogenic factors.
Many Questions Arise
What factors impede the potential oncogenic functions of RAS in granulosa cells and direct the cells to exit the cell cycle? Are the cell cycle-arrested granulosa cells present in the abnormal follicle-like structures quiescent, senescent, or prematurely terminally differentiated? Granulosa cells of preovulatory follicles respond to activation of RAS, ERK1/2, and C/EBP␤ and cease dividing and become terminally differentiated luteal cells. Therefore, it is tempting to speculate that granulosa cells of small follicles expressing of KRAS G12D respond to the same factors in a similar manner. But are they terminally differentiated? The answer is probably no, because with the exception of PTEN, the cell cycle-arrested granulosa cells present in the abnormal follicles do not express known granulosa cell or luteal cell markers (12, 28) .
Would disruption of endogenous KRAS alter follicle development, ovulation, or luteinization? The answer is probably yes, based on the potent, global effects of ERK1/2, a downstream target of RAS in granulosa cells. We would predict that a phenotype similar to the Erk1/2 mutant mice (34) would be observed, assuming that other members of the RAS family do not compensate for KRAS. This is likely because the expression of KRAS G12D alone in granulosa cells of small follicles silenced the endogenous Kras gene, leading to cell cycle arrest and the absence of ERK1/2 and AKT phosphorylation (19) . One might not expect such a dramatic alteration of granulosa cell fate, if other RAS proteins maintained functional RAS activity. Moreover, recent studies have revealed marked functional differences among the highly related Ras family oncogenes. For example, nearly 50% of colon cancers harbor activating mutations in Kras, whereas Nras mutations occur in a smaller percentage (5%) (48) . Conditional expression of Kras G12D in the colonic epithelium stimulated hyperproliferation in a MEK-dependent manner. Nras G12D did not alter the growth properties of the epithelium but was able to confer resistance to apoptosis (48) . However, it is unclear whether the Nras G12D mutant can induce the same changes in ovarian granulosa and epithelial cells, as the Kras G12D does. Because Hras and Nras knockout mice are viable and fertile, we predict that these two Ras family members are unlikely to play an essential role in the ovary. Thus, it will be important to analyze the ovarian functions of endogenous Kras by using the Loxp-Cre system to selectively deplete Kras in granulosa cells. This Kras loss-of-function study will provide the valuable in vivo information complementary to the Kras G12D gain-of-function studies we have conducted. Does KRAS G12D exert different effects in cells of other endocrine tissues than it does in epithelial cells and fibroblasts? The answer is probably yes, because KRAS G12D causes premature cell cycle arrest as well as terminal differentiation of granulosa cells and because these cells do not express known markers of senescence, such as senescent-associated (SA)-␤-galactosidase. Thus, these cells do not appear to be senescent (14, 15) . Curiously, however, the terminal differentiation of granulosa cells to luteal cells (36, 41) , stromal cells to decidual cells (37) , and preadipocytes to adipocytes (38) appears to be mediated by potent cytokines and C/EBP␤, factors that also impact cell senescence and are markers of epithelial and fibroblast senescent cells (40, 80) . A major difference is that RAS-induced senescent epithelial cells continue to produce copious amounts of cytokines (80) and continue to express the KRAS gene, whereas terminally differentiated granulosa cells do not.
Are the effects of Kras G12D on cell cycle arrest dominant in granulosa cells but not OSE cells? The answer is probably yes, because GCTs arise in Pten/Ctnnb1 mutant ovaries (75) but not in Pten/Kras mutant ovaries (19) . These observations suggest that the cell cycle arrest power of KRAS G12D is dominant to the potential tumorigenic (proliferative and antiapoptotic) effects of mutant Pten. By contrast, Ctnnb1 and Pten mutations synergize to facilitate rampant proliferation of granulosa cells. Therefore, it is possible that Kras G12D would also impede or reduce the tumorigenic effects of Ctnnb1 or mutations of Smad1, 5, or 8 or inhibin ␣ in granulosa cells. These analyses remain to be done. Furthermore, the ovarian cell-specific, Kras, Pten, and Ctnnb1 mutant mice afford unique mouse models in which to analyze the molecular (mRNA and micro-RNA) and endocrine (hormone-dependent?) basis for tumor formation in OSE cells compared with the molecular and endocrine events that cause cell cycle arrest in granulosa cells. The Pten/Kras double-mutant mouse strain provides a potentially important model for OSE cancer because the onset and progression of OSE cell transformation in response to these oncogenes remains to be clearly defined. Multiple Ras downstream effectors such as the PI3K and ERK1/2 pathways are hyperactive in the OSE tumor cells (19) . The contributions of each effector to the oncogenic transformation of OSE cells may lead to the discovery of new targets for cancer therapy concerning cancer.
Taken together, these studies of Kras in mammalian ovarian cells provide novel information relevant to how the RAS family of small G proteins may contribute to specific physiological and pathological processes within the ovary. The data clearly demonstrate the potent impact of endogenous RAS (KRAS) in regulating important physiological (follicle development and ovulation) events and the impact of mutant KRAS in dictating pathological (premature ovarian failure and OSE adenocarcinomas) outcomes. Hopefully, a better understanding of the molecular targets of RAS in specific ovarian cell types will build a bridge between normal reproductive biology and cancer biology in the ovary. Fan 
